Want to see PHR full AI Analyst Report?

Phreesia (PHR) Stock Forecast & Price Target

371 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PHR Analyst Ratings

Moderate Buy

3 Buy

3 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Phreesia

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PHR Stock 12 Month Forecast

Average Price Target

$13.60

▲(16.34% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $13.60 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 16.34% change from the last price of $11.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","13.25":"$13.25","19.5":"$19.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.25,19.5,25.75,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,11.135384615384616,11.54076923076923,11.946153846153846,12.351538461538462,12.756923076923076,13.162307692307692,13.567692307692308,13.973076923076924,14.378461538461538,14.783846153846154,15.189230769230768,15.594615384615384,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,10.95076923076923,11.171538461538463,11.392307692307693,11.613076923076923,11.833846153846153,12.054615384615385,12.275384615384615,12.496153846153845,12.716923076923077,12.937692307692307,13.158461538461538,13.37923076923077,{"y":13.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,10.673846153846155,10.617692307692309,10.561538461538461,10.505384615384616,10.44923076923077,10.393076923076924,10.336923076923076,10.28076923076923,10.224615384615385,10.168461538461539,10.112307692307692,10.056153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$13.60

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan MacDonald

Needham

$14

Buy

19.76%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (NASDAQ: PAHC) and Phreesia (NYSE: PHR)

Richard Close

Canaccord Genuity

$16

Buy

36.87%

Upside

Reiterated

08/11/26

Phreesia (PHR) Gets a Buy from Canaccord Genuity

Alexei Gogolev

J.P. Morgan

$14

Hold

19.76%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)

Sean Dodge

BMO Capital

$14

Buy

19.76%

Upside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

Glen Santangelo

Barclays

$10

Hold

-14.46%

Downside

Reiterated

06/15/26

Barclays Sticks to Their Hold Rating for Phreesia (PHR)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$20

Buy

71.09%

Upside

Reiterated

05/28/26

Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)

Clark Wright

D.A. Davidson

$14

Buy

19.76%

Upside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)

Daniel Grosslight

Citi

$10→$12

Hold

2.65%

Upside

Reiterated

05/28/26

Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi

Stan Berenshteyn

Wells Fargo

Hold

-23.01%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)

Jessica Tassan

Piper Sandler

$23→$12

Hold

2.65%

Upside

Downgraded

05/28/26

Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler

Ryan Halsted

RBC Capital

$19

Buy

62.53%

Upside

Reiterated

05/27/26

RBC Capital Remains a Buy on Phreesia (PHR)

Scott Schoenhaus

KeyBanc

$15→$12

Buy

2.65%

Upside

Assigned

04/13/26

Phreesia (PHR) Gets a Buy from KeyBanc

Aaron Kimson

Citizens JMP

―

Hold

―

Downgraded

04/01/26

Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan MacDonald

Needham

$14

Buy

19.76%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (NASDAQ: PAHC) and Phreesia (NYSE: PHR)

Richard Close

Canaccord Genuity

$16

Buy

36.87%

Upside

Reiterated

08/11/26

Phreesia (PHR) Gets a Buy from Canaccord Genuity

Alexei Gogolev

J.P. Morgan

$14

Hold

19.76%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)

Sean Dodge

BMO Capital

$14

Buy

19.76%

Upside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

Glen Santangelo

Barclays

$10

Hold

-14.46%

Downside

Reiterated

06/15/26

Barclays Sticks to Their Hold Rating for Phreesia (PHR)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$20

Buy

71.09%

Upside

Reiterated

05/28/26

Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)

Clark Wright

D.A. Davidson

$14

Buy

19.76%

Upside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)

Daniel Grosslight

Citi

$10→$12

Hold

2.65%

Upside

Reiterated

05/28/26

Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi

Stan Berenshteyn

Wells Fargo

Hold

-23.01%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)

Jessica Tassan

Piper Sandler

$23→$12

Hold

2.65%

Upside

Downgraded

05/28/26

Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler

Ryan Halsted

RBC Capital

$19

Buy

62.53%

Upside

Reiterated

05/27/26

RBC Capital Remains a Buy on Phreesia (PHR)

Scott Schoenhaus

KeyBanc

$15→$12

Buy

2.65%

Upside

Assigned

04/13/26

Phreesia (PHR) Gets a Buy from KeyBanc

Aaron Kimson

Citizens JMP

―

Hold

―

Downgraded

04/01/26

Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Phreesia

3 Months

John RansomRaymond James

Success Rate

9/16 ratings generated profit

Average Return

+0.33%

Copying John Ransom's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +0.33% per trade.

1 Year

Ryan DanielsWilliam Blair

Success Rate

4/9 ratings generated profit

Average Return

-11.92%

Copying Ryan Daniels's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -11.92% per trade.

2 Years

Ryan DanielsWilliam Blair

Success Rate

4/9 ratings generated profit

Average Return

+4.91%

Copying Ryan Daniels's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +4.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHR Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PHR has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PHR average Analyst price target in the past 3 months is 13.60.

Each month's total comprises the sum of three months' worth of ratings.

PHR Financial Forecast

PHR Earnings Forecast

Currently, no earnings data available.

PHR Sales Forecast

Currently, no sales data available.

PHR Stock Forecast FAQ

What is PHR’s average 12-month price target, according to analysts?

Based on analyst ratings, Phreesia’s 12-month average price target is 13.60.

What is PHR’s upside potential, based on the analysts’ average price target?

Phreesia has 16.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PHR a Buy, Sell or Hold?

Phreesia has a consensus rating of Moderate Buy which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.

What is Phreesia’s price target?

The average price target for Phreesia is 13.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $10.00. The average price target represents 16.34% Increase from the current price of $11.69.

What do analysts say about Phreesia?

Phreesia’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of PHR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Phreesia (PHR) Stock Forecast & Price Target

PHR Analyst Ratings

PHR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Phreesia

PHR Analyst Recommendation Trends

PHR Financial Forecast

PHR Earnings Forecast

PHR Sales Forecast

PHR Stock Forecast FAQ

Detailed List of Analyst Forecasts